5 February 2024
Scancell Holdings
plc
("Scancell" or the "Company")
Directorate Change and
Appointment of Head of Development
· Dr
Sally Adams to retire as an Executive
Director of the Board and as Chief Development Officer
· Dr
Callum Scott has been appointed as Head of Development
Scancell Holdings plc (AIM: SCLP),
the developer of novel immunotherapies for the treatment of cancer
and infectious disease, today announces that Dr Sally Adams is
retiring as an Executive Director of the Board and as Chief
Development Officer. Dr Callum Scott has been appointed as the new Head of
Development, effective immediately, and Sally will remain with the
Company part time for 6 months to ensure a smooth and effective
transition of responsibilities.
Dr Scott brings over 15 years of
experience in vaccine research and development. Previously, he held
the role of Technical Transfer & Formulation Development
Manager at UK biotech firm Allergy Therapeutics (AIM:
AGY) where he led all CMC (Chemistry,
Manufacturing and Controls)/product development activities relating
to their VLP Peanut project through Phases 1-3 including IND
approvals. Dr Scott holds a PhD in Molecular Microbiology and a BSc
in Biochemistry, both from Heriot-Watt University.
Prof Lindy Durrant, Chief Executive Officer of
Scancell, commented: "Firstly, on behalf of the Scancell Board, I
would like to express our sincere gratitude to Sally for her
expertise and support over the last 15 years, both on the Board and
leading clinical development. She has been instrumental in
establishing a highly motivated development team and has worked
tirelessly to bring our highly differentiated and valuable cancer
vaccines through to the clinic. We wish her all the best for the
future.
"I
would also like to warmly welcome Callum to Scancell. His
understanding of the challenges involved in developing,
registering, and commercialising novel biologics will be of great
value to Scancell as we continue to develop our lead assets SCIB1
and Modi-1 through later stage clinical
development."
Dr
Sally Adams, Chief Development Officer, said:
"It has been a privilege to work with Lindy and
the Scancell team for the last 15 years, helping to develop
successful manufacturing processes and quality systems and to take
three products into the clinic. The recent clinical successes with
SCIB1 and Modi-1 have been the culmination of a huge team effort
across the Company, and I have every confidence that these results
will be built upon in the future. I wish Lindy and the Company
every success."
Dr
Callum Scott, Head of Development, commented:
"Joining Scancell when SCIB1 and Modi-1 cancer
vaccines are making highly promising clinical progress is very
exciting, with further data from the SCOPE study expected in
mid-2024 and ModiFY trial later this year. I look forward to
contributing to the rapid advancement of these innovative and
high-value assets through the clinic and towards commercialisation
and working with Lindy and the Scancell team."
|
For
further information, please contact:
|
|
|
|
|
|
Scancell Holdings plc
|
+44 (0) 20 3709 5700
|
|
Dr Jean-Michel Cosséry,
Non-Executive Chairman
|
|
|
Professor Lindy Durrant,
CEO
|
|
|
|
|
|
Stifel Nicolaus Europe Limited (Nominated Adviser and Joint Broker)
|
+44 (0) 20 7710 7600
|
|
Nicholas Moore/Samira
Essebiyea/William Palmer-Brown (Healthcare Investment
Banking)
|
|
|
Nick Adams/Nick Harland (Corporate
Broking)
|
|
|
WG
Partners LLP (Joint Broker)
David Wilson/Claes Spang/Sathesh
Nadarajah/Erland Sternby
|
+44 (0) 20 3705 9330
|
|
Panmure Gordon (UK) Limited (Joint Broker)
|
+44 (0) 20 7886 2500
|
|
Freddy Crossley/Emma Earl (Corporate
Finance)
|
|
|
Rupert Dearden (Corporate
Broking)
|
|
|
|
|
|
ICR
Consilium
|
+44 (0) 20 3709 5700
|
|
Mary-Jane Elliott/Matthew Neal/Chris
Welsh
|
scancell@consilium-comms.com
|
About Scancell
Scancell is a clinical stage
biopharmaceutical company that is leveraging its proprietary
research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant
unmet needs in cancer and infectious disease. The Company is
building a pipeline of innovative products by utilising its four
technology platforms: Moditope® and
ImmunoBody® for vaccines and GlyMab® and
AvidiMab® for antibodies.
Adaptive immune responses include
antibodies and T cells (CD4 and CD8), both of which can recognise
damaged or infected cells. In order to destroy such cancerous or
infected cells, Scancell uses either vaccines to induce immune
responses or monoclonal antibodies (mAbs) to redirect immune cells
or drugs. The Company's unique approach is that its innovative
products target modifications of proteins and lipids. For the
vaccines (Moditope® and ImmunoBody®) this
includes citrullination and homocitrullination of proteins, whereas
its mAb portfolio targets glycans or sugars that are added onto
proteins and / or lipids (GlyMab®) or enhances the
potency of antibodies and their ability to directly kill tumour
cells (AvidiMab®).
For further information about
Scancell, please visit: https://www.scancell.co.uk/
